TP53 and neoplasm: However, NGS analysis of 155 ALK/RET/ROS1-rearranged NSCLC patients revealed TP53 mutations and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) copy number loss, impacting the tumor immune microenvironment and clinical outcomes.